The microglial dysfunction hypothesis represents a critical paradigm shift in understanding Alzheimer’s disease (AD) pathogenesis. Traditionally viewed as a secondary inflammatory response to amyloid-beta (Aβ) deposition, microglia are now recognized as central drivers of neurodegeneration through their dysregulated functions in immune surveillance, synaptic pruning, and metabolic support.
Overview
flowchart TD
Microglial_Dysfunction_in_Alzh["Microglial Dysfunction in Alzheimers Disease"]
Microglial_Dysfunction_in_Alzh["Alzheimer"]
Microglial_Dysfunction_in_Alzh -->|"related to"| Microglial_Dysfunction_in_Alzh
style Microglial_Dysfunction_in_Alzh fill:#81c784,stroke:#333,color:#000
Microglial_Dysfunction_in_Alzh["represents"]
Microglial_Dysfunction_in_Alzh -->|"related to"| Microglial_Dysfunction_in_Alzh
style Microglial_Dysfunction_in_Alzh fill:#81c784,stroke:#333,color:#000
Microglial_Dysfunction_in_Alzh["critical"]
Microglial_Dysfunction_in_Alzh -->|"related to"| Microglial_Dysfunction_in_Alzh
style Microglial_Dysfunction_in_Alzh fill:#81c784,stroke:#333,color:#000
style Microglial_Dysfunction_in_Alzh fill:#4fc3f7,stroke:#333,color:#000Microglia are the resident immune cells of the central nervous system (CNS), derived from yolk sac progenitors that colonize the brain during embryonic development
The microglial dysfunction hypothesis posits that age-related or genetic factors cause microglia to enter a maladaptive state characterized by:
-
Chronic pro-inflammatory activation
-
Impaired Abeta clearance
-
Dysregulated synaptic pruning
-
Metabolic dysfunction
-
Loss of homeostatic functions
TREM2 and TYROBP Signaling Pathway
TREM2 Structure and Function
Triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane receptor expressed exclusively on microglia in the brain1TREM2 in myeloid cells (2000)Open reference. It belongs to the immunoglobulin superfamily and partners with the adaptor protein TYROBP (also known as DAP12) to transduce extracellular signals into cellular responses2DAP12 signaling (2009)Open reference.
TREM2 possesses an extracellular ligand-binding domain, a transmembrane helix, and a cytoplasmic tail that interacts with TYROBP’s immunoreceptor tyrosine-based activation motif (ITAM)3TREM2 structure (2016)Open reference. Upon ligand binding, SYK kinase is recruited and activated, triggering downstream signaling cascades involving PLCγ, CARD9, and NF-κB4TREM2 signaling cascade (2010)Open reference.
TREM2 Ligands
Several ligands have been identified for TREM2:
-
Apolipoprotein E (ApoE): TREM2 binds to lipidated ApoE, which is heavily produced by microglia in response to injury5TREM2 binds apolipoprotein E (2015)Open reference
-
Amyloid-beta: Aβ oligomers and fibrils can engage TREM2, providing a direct link between amyloid pathology and microglial activation6TREM2 recognizes Aβ oligomers (2018)Open reference
-
Phospholipids: Exposed phospholipids on apoptotic cells serve as danger-associated molecular patterns (DAMPs)7TREM2 and phospholipids (2014)Open reference
-
TREM2 ligands from neurons: Neuronal activity may release TREM2 ligands that modulate microglial function8Neuronal TREM2 ligands (2019)Open reference
TYROBP (DAP12) Adaptor Protein
TYROBP is a transmembrane adaptor protein containing an ITAM that becomes phosphorylated upon TREM2 activation9TYROBP adaptor protein (2012)Open reference. The TREM2-TYROBP complex activates:
-
SYK kinase: Central kinase downstream of ITAM phosphorylation10SYK kinase signaling (2010)Open reference
-
PI3K/AKT pathway: Promotes cell survival and metabolic function2DAP12 signaling (2009)Open reference0
-
MAPK signaling: Regulates gene expression and inflammatory responses2DAP12 signaling (2009)Open reference1
-
NF-κB activation: Controls pro-inflammatory cytokine transcription2DAP12 signaling (2009)Open reference2
TREM2 Variants and AD Risk
Rare coding variants in TREM2 significantly increase AD risk, with the R47H variant conferring approximately 3-fold increased odds2DAP12 signaling (2009)Open reference3. This variant impairs TREM2’s ability to bind its ligands, particularly ApoE and Aβ, demonstrating the critical role of microglial immune sensing in AD pathogenesis2DAP12 signaling (2009)Open reference4.
Other TREM2 risk variants include:
-
R62H: Associated with moderate AD risk increase2DAP12 signaling (2009)Open reference5
-
D87N: Loss-of-function variant linked to enhanced disease susceptibility2DAP12 signaling (2009)Open reference6
-
Y38C: Impaired signaling capacity2DAP12 signaling (2009)Open reference7
Disease-Associated Microglia (DAM)
DAM Phenotype
The Disease-Associated Microglia (DAM) program represents a distinct microglial transcriptional state activated in response to neurodegeneration2DAP12 signaling (2009)Open reference8. DAM cells are characterized by upregulation of genes involved in:
-
Phagocytosis: CD68, C1qa, C1qb, Hexosaminidase subunit beta (HEXB)2DAP12 signaling (2009)Open reference9
-
Lipid metabolism: Apolipoprotein E (APOE), Lipoprotein lipase (LPL)3TREM2 structure (2016)Open reference0
-
炎症反应: Trem2, Tyrobp, Clec7a3TREM2 structure (2016)Open reference1
-
Iron handling: Ferritin heavy chain (FTH1), Ferritin light chain (FTL)3TREM2 structure (2016)Open reference2
DAM Stages
The DAM program develops in a two-stage progression:
Stage 1 (TREM2-independent): Initial activation characterized by upregulation of Type I interferon-responsive genes and gradual upregulation of some DAM genes. This stage occurs even in the absence of functional TREM23TREM2 structure (2016)Open reference3.
Stage 2 (TREM2-dependent): Full DAM differentiation requires TREM2 signaling. This stage involves dramatic upregulation of phagocytic genes, lipid metabolism genes, and genes involved in lysosomal function3TREM2 structure (2016)Open reference4.
Microglial Clusters in AD
Single-cell RNA sequencing has revealed multiple microglial subpopulations in AD brain tissue3TREM2 structure (2016)Open reference5:
-
Cluster 1: Age-related microglia (ARM) - associated with aging rather than disease3TREM2 structure (2016)Open reference6
-
Cluster 2: Inflammatory microglia - expressing high levels of IL1B, CCL2, and other pro-inflammatory mediators3TREM2 structure (2016)Open reference7
-
Cluster 3: Aβ-responsive microglia - specifically upregulated in proximity to amyloid plaques3TREM2 structure (2016)Open reference8
-
Cluster 4: Neural microglia - expressing synaptic function-related genes3TREM2 structure (2016)Open reference9
Neuroinflammation Feedback Loops
Chronic Microglial Activation
In AD, microglia become trapped in a chronic pro-inflammatory state characterized by sustained production of:
-
Interleukin-1β (IL-1β): Drives neuronal stress response and promotes tau pathology4TREM2 signaling cascade (2010)Open reference0
-
Tumor necrosis factor-α (TNF-α): Induces synaptic dysfunction and neuronal death4TREM2 signaling cascade (2010)Open reference1
-
Interleukin-6 (IL-6): Impairs neurogenesis and promotes Aβ production4TREM2 signaling cascade (2010)Open reference2
-
CCL2/MCP-1: Recruits additional inflammatory cells and promotes neurotoxicity4TREM2 signaling cascade (2010)Open reference3
Amplification Loops
Aβ-IL-1β Loop: Aβ deposition triggers microglial IL-1β production, which in turn increases amyloid precursor protein (APP) expression and Aβ generation by neurons4TREM2 signaling cascade (2010)Open reference4.
Tau-IL-1β Loop: IL-1β promotes tau hyperphosphorylation and propagation, while tau aggregates can activate microglia through TREM2-independent pathways4TREM2 signaling cascade (2010)Open reference5.
NLRP3 Inflammasome: Microglial NLRP3 activation by Aβ creates a self-amplifying inflammatory cascade that drives chronic neuroinflammation4TREM2 signaling cascade (2010)Open reference6.
Microglial-Neuronal Cross-Talk
Dysfunctional microglia lose their ability to support neuronal health:
-
Impaired synaptic pruning: Microglial complement proteins (C1q, C3) tag synapses for elimination, but dysregulated pruning in AD leads to excessive synapse loss4TREM2 signaling cascade (2010)Open reference7
-
Growth factor deprivation: Microglia normally produce BDNF and other trophic factors; this function is lost in the DAM state4TREM2 signaling cascade (2010)Open reference8
-
Ion homeostasis: Microglial dysfunction contributes to extracellular K+ accumulation and neuronal hyperexcitability4TREM2 signaling cascade (2010)Open reference9
Therapeutic Implications
TREM2-Targeting Strategies
Several therapeutic approaches target the TREM2 pathway:
-
TREM2 agonistic antibodies: Activate TREM2 signaling to promote microglial Aβ clearance5TREM2 binds apolipoprotein E (2015)Open reference0
-
TREM2 decoy receptors: Soluble TREM2 (sTREM2) may have protective functions5TREM2 binds apolipoprotein E (2015)Open reference1
-
Small molecule TREM2 activators: Currently in development5TREM2 binds apolipoprotein E (2015)Open reference2
Anti-inflammatory Approaches
-
CSF1R antagonists: Deplete dysfunctional microglia while allowing replacement with healthy cells5TREM2 binds apolipoprotein E (2015)Open reference3
-
NLRP3 inhibitors: Target the inflammasome-driven inflammatory cascade5TREM2 binds apolipoprotein E (2015)Open reference4
-
Minocycline: Broad-spectrum anti-inflammatory effects on microglia5TREM2 binds apolipoprotein E (2015)Open reference5
Microglial Metabolism in AD
Metabolic Reprogramming
AD-associated microglia undergo dramatic metabolic changes that impair their function5TREM2 binds apolipoprotein E (2015)Open reference6. Under normal conditions, microglia rely primarily on oxidative phosphorylation (OXPHOS) for energy production. However, in the DAM state, microglia shift toward aerobic glycolysis, a metabolic program typically associated with immune activation5TREM2 binds apolipoprotein E (2015)Open reference7.
This metabolic shift has several consequences:
-
Lactate accumulation: Increased glycolysis leads to lactate production, which can acidify the extracellular environment and promote neuronal dysfunction5TREM2 binds apolipoprotein E (2015)Open reference8
-
Impaired OXPHOS: Mitochondrial function becomes compromised, reducing ATP production capacity5TREM2 binds apolipoprotein E (2015)Open reference9
-
NAD+ depletion: Rapid consumption of NAD+ in glycolysis disrupts cellular homeostasis6TREM2 recognizes Aβ oligomers (2018)Open reference0
Lipid Metabolism Dysregulation
Microglia in AD show profound alterations in lipid metabolism6TREM2 recognizes Aβ oligomers (2018)Open reference1. The TREM2 pathway is intimately connected to lipid handling:
-
Cholesterol accumulation: Foam cell formation in AD microglia mirrors atherosclerotic plaque development6TREM2 recognizes Aβ oligomers (2018)Open reference2
-
Oxidized lipids: Accumulation of oxidized phospholipids serves as a DAM trigger6TREM2 recognizes Aβ oligomers (2018)Open reference3
-
Eicosanoid production: Pro-inflammatory eicosanoids amplify neuroinflammation6TREM2 recognizes Aβ oligomers (2018)Open reference4
Mitochondrial Dysfunction
Mitochondrial abnormalities in AD microglia include:
-
Mitochondrial fragmentation: Increased DRP1-mediated fission impairs mitochondrial quality control6TREM2 recognizes Aβ oligomers (2018)Open reference5
-
Reduced mtDNA copy number: Depleted mitochondrial DNA compromises OXPHOS capacity6TREM2 recognizes Aβ oligomers (2018)Open reference6
-
Accumulation of mutant mtDNA: Clonal expansion of mutant mitochondria in affected brain regions6TREM2 recognizes Aβ oligomers (2018)Open reference7
Research Directions and Future Perspectives
Single-Cell Technologies
Advanced single-cell approaches are revealing unprecedented detail about microglial heterogeneity in AD6TREM2 recognizes Aβ oligomers (2018)Open reference8:
-
Spatial transcriptomics: Mapping gene expression in situ reveals microglial states in relationship to pathology6TREM2 recognizes Aβ oligomers (2018)Open reference9
-
Single-cell ATAC-seq: Chromatin accessibility profiling identifies regulatory elements controlling DAM programs7TREM2 and phospholipids (2014)Open reference0
-
Multi-omics integration: Combining transcriptomics, proteomics, and epigenomics provides holistic understanding7TREM2 and phospholipids (2014)Open reference1
Microglial Replacement Therapies
Emerging strategies aim to replace dysfunctional microglia with healthy cells7TREM2 and phospholipids (2014)Open reference2:
-
Bone marrow transplantation: Hematopoietic stem cell therapy shows promise in preclinical models7TREM2 and phospholipids (2014)Open reference3
-
Induced microglia-like (iMG) cells: Patient-derived iMG cells offer personalized therapeutic potential7TREM2 and phospholipids (2014)Open reference4
-
Microglial stem cell therapy: Pluripotent stem cell-derived microglia for transplantation7TREM2 and phospholipids (2014)Open reference5
Biomarker Development
Microglial biomarkers are being developed for AD diagnosis and monitoring7TREM2 and phospholipids (2014)Open reference6:
-
sTREM2 in CSF: Soluble TREM2 levels correlate with disease progression7TREM2 and phospholipids (2014)Open reference7
-
PET ligands: Microglial activation imaging with TSPO-PET reveals inflammatory burden7TREM2 and phospholipids (2014)Open reference8
-
Blood biomarkers: Peripheral immune markers reflect CNS microglial activation7TREM2 and phospholipids (2014)Open reference9
Conclusion
The microglial dysfunction hypothesis has transformed our understanding of AD pathogenesis by positioning microglia as central drivers rather than passive responders to pathology. The TREM2-TYROBP signaling pathway provides a molecular bridge connecting genetic risk factors to microglial dysfunction, while the DAM program reveals the complex phenotypic changes that characterize disease-associated microglial states. Understanding the neuroinflammation feedback loops that perpetuate microglial dysfunction, coupled with insights into metabolic reprogramming, offers promising therapeutic targets for disease-modifying interventions in AD. The emergence of single-cell technologies and microglial replacement therapies heralds a new era of precision immunology approaches to neurodegeneration.
See Also
External Links
References
- TREM2 in myeloid cells (2000)
- DAP12 signaling (2009)
- TREM2 structure (2016)
- TREM2 signaling cascade (2010)
- TREM2 binds apolipoprotein E (2015)
- TREM2 recognizes Aβ oligomers (2018)
- TREM2 and phospholipids (2014)
- Neuronal TREM2 ligands (2019)
- TYROBP adaptor protein (2012)
- SYK kinase signaling (2010)
- TREM2 PI3K/AKT pathway (2017)
- TREM2 MAPK signaling (2018)
- TREM2 NF-κB activation (2016)
- TREM2 variants in AD (2013)
- TREM2 R47H variant (2013)
- TREM2 R62H variant (2016)
- TREM2 D87N functional analysis (2018)
- TREM2 Y38C variant function (2019)
- Disease-associated microglia (2017)
- Microglial phagocytosis (2013)
- Microglial lipid metabolism in AD (2018)
- CLEC7A in neuroinflammation (2020)
- Neuroinflammation and iron metabolism (2017)
- TREM2-independent DAM stage (2017)
- TREM2-dependent DAM program (2020)
- Single-cell microglial states in AD (2019)
- Age-related microglia (2018)
- Inflammatory microglia (2019)
- Aβ-responsive microglia (2019)
- Neural microglia (2020)
- IL-1β in AD (2003)
- TNF-α neurotoxicity (2006)
- IL-6 in CNS disorders (2010)
- CCL2 in neuroinflammation (2010)
- Aβ-IL-1β feedback loop (2011)
- Tau-IL-1β loop in AD (2019)
- NLRP3 inflammasome in AD (2013)
- Complement and synaptic pruning (2013)
- Microglial BDNF production (2018)
- Microglial ion homeostasis (2020)
- TREM2 antibody therapy (2020)
- Soluble TREM2 (2021)
- TREM2 small molecule activators (2020)
- CSF1R antagonist depletion (2018)
- NLRP3 inhibitors in AD (2015)
- Minocycline in AD models (2007)
- Microglial metabolic reprogramming (2019)
- Glycolysis in neuroinflammation (2020)
- Lactate and brain function (2014)
- Mitochondrial dysfunction in AD microglia (2019)
- NAD+ metabolism in neurodegeneration (2018)
- Microglial lipid metabolism in AD (2020)
- Microglial foam cells in AD (2014)
- Oxidized lipids as DAM triggers (2018)
- Eicosanoids in neuroinflammation (2019)
- Mitochondrial dynamics in AD (2017)
- Mitochondrial DNA depletion in AD (2018)
- Mitochondrial mutations in AD (2020)
- Microglial single-cell analysis (2020)
- Spatial transcriptomics of microglia (2021)
- Microglial chromatin accessibility (2021)
- Multi-omics of microglia in AD (2022)
- Microglial replacement therapy (2020)
- Bone marrow microglia transplantation (2019)
- Induced microglia-like cells (2020)
- Microglial stem cell therapy (2021)
- Microglial biomarkers in AD (2019)
- CSF sTREM2 and disease progression (2020)
- TSPO PET microglial activation (2016)
- Blood microglial biomarkers (2020)
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.